---

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

(Mark One)

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarter Ended June 30, 2014

 

or

 

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

 

Commission File Number 000-09273

 

MOCON, INC.

(Exact name of registrant as specified in its charter)

 

Minnesota		41-0903312
(State or other jurisdiction of		(I.R.S. employer
incorporation or organization)		identification no.)

 

7500 Mendelssohn Avenue North, Minneapolis, Minnesota 55428

(Address of principal executive offices)        (Zip code)

 

(763) 493-6370

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

YES ☒ NO ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

YES ☒ NO ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer (do not check if a smaller reporting company) ☐ Smaller reporting company ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

YES ☐ NO ☒

 

 

As of August 4, 2014, the Company had 5,662,421 common shares issued and outstanding.

 

---

---

 

 

MOCON, INC. AND SUBSIDIARIES

 

INDEX TO FORM 10-Q

For the Quarter Ended June 30, 2014

 

		Page Number
PART I.      FINANCIAL INFORMATION
Item 1.	Financial Statements
	Condensed Consolidated Balance Sheets June 30, 2014 (Unaudited) and December 31, 2013	1
	Condensed Consolidated Statements of Income (Unaudited) Three and six months ended June 30, 2014 and 2013	2
	Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three and six months ended June 30, 2014 and 2013	3
	Condensed Consolidated Statements of Cash Flows (Unaudited) Six months ended June 30, 2014 and 2013	4
	Notes to Condensed Consolidated Financial Statements (Unaudited)	5-14
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15-24
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24-25
Item 4.	Controls and Procedures	25
PART II.     OTHER INFORMATION
Item 1.	Legal Proceedings	25
Item 1A.	Risk Factors	25
Item 2.	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities	26
Item 3.	Defaults Upon Senior Securities	26
Item 4.	Mine Safety Disclosures	26
Item 5.	Other Information	26
Item 6.	Exhibits	26
Signatures		27
Exhibit Index		28

 

In this report, references to “MOCON,” “the Company,” “we,” “our,” or “us,” unless the context otherwise requires, refer to MOCON, Inc. and its subsidiaries. 

 

All trademarks or trade names referred to in this report are the property of their respective owners.

  

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

MOCON, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

		June 30,
		2014				December 31,
		(Unaudited)				2013
ASSETS
Current assets:
Cash and cash equivalents		$	5,453,386			$	4,132,953
Marketable securities, current			-				205,000
Trade accounts receivable, less allowance for doubtful accounts of $298,235 in 2014 and $315,417 in 2013			10,498,008				12,335,124
Other receivables			389,291				273,405
Inventories			8,498,018				7,470,697
Prepaid income taxes			548,704				595,898
Prepaid expenses, other			1,113,502				1,126,582
Deferred income taxes			1,176,862				1,429,794
Total current assets			27,677,771				27,569,453
Property, plant and equipment, net of accumulated depreciation of $8,283,620 in 2014 and $7,811,276 in 2013			5,912,479				5,726,754
Goodwill			8,970,733				9,034,479
Investment in affiliated company			3,411,251				3,441,500
Intangible assets, net			12,325,049				12,718,203
Other assets			203,583				213,279
TOTAL ASSETS		$	58,500,866			$	58,703,668
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current maturities of notes payable		$	1,892,812			$	2,697,678
Revolving lines of credit			4,848,752				4,263,821
Accounts payable			3,412,024				3,864,355
Compensation and related expenses			3,510,191				3,752,542
Other accrued expenses			853,273				781,151
Accrued product warranties			230,687				335,533
Dividends payable			622,856				619,322
Deferred revenue			1,440,226				620,428
Total current liabilities			16,810,821				16,934,830
Notes payable			762,104				1,306,849
Obligations to former employees			76,657				77,334
Deferred income taxes			2,198,527				2,611,491
Accrued income taxes			319,910				304,424
Total noncurrent liabilities			3,357,198				4,300,098
Total liabilities			20,168,019				21,234,928
Stockholders' equity:
Capital stock – undesignated. Authorized 3,000,000 shares; none issued and outstanding in 2014 and 2013			-				-
Common stock – $0.10 par value. Authorized 22,000,000 shares; issued and outstanding 5,662,326 shares in 2014 and 5,630,197 shares in 2013			566,233				563,020
Additional paid-in capital			5,529,125				5,063,627
Retained earnings			31,878,285				31,229,068
Accumulated other comprehensive income			359,204				613,025
Total stockholders' equity			38,332,847				37,468,740
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		$	58,500,866			$	58,703,668

 

See accompanying notes to condensed consolidated financial statements.

 

 

MOCON, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

 

 

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2014				2013				2014				2013
Sales:
Products		$	14,869,239			$	12,946,714			$	29,511,029			$	26,688,295
Consulting services			705,284				741,301				1,376,642				1,446,898
Total sales			15,574,523				13,688,015				30,887,671				28,135,193
Cost of sales:
Products			6,343,866				5,605,548				12,811,120				11,613,449
Consulting services			508,294				426,197				965,397				887,972
Total cost of sales			6,852,160				6,031,745				13,776,517				12,501,421
Gross profit			8,722,363				7,656,270				17,111,154				15,633,772
Selling, general and administrative expenses			5,947,087				5,667,505				12,090,372				11,270,910
Research and development expenses			989,402				1,079,545				2,114,277				2,198,294
Operating income			1,785,874				909,220				2,906,505				2,164,568
Other income (expense), net			(93,354	)			(86,303	)			(150,182	)			(190,682	)
Income before income taxes			1,692,520				822,917				2,756,323				1,973,886
Income tax expense			527,261				21,271				861,347				305,638
Net income		$	1,165,259			$	801,646			$	1,894,976			$	1,668,248
Net income per common share:
Basic		$	0.21			$	0.14			$	0.34			$	0.30
Diluted		$	0.20			$	0.14			$	0.33			$	0.29
Weighted average common shares outstanding:
Basic			5,655,146				5,537,677				5,648,025				5,529,430
Diluted			5,774,748				5,671,845				5,770,207				5,669,016
Cash dividends declared per common share		$	0.11			$	0.11			$	0.22			$	0.22

 

See accompanying notes to condensed consolidated financial statements.

 

 

MOCON, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

 

 

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2014				2013				2014				2013
Net income		$	1,165,259			$	801,646			$	1,894,976			$	1,668,248
Other comprehensive income (loss):
Cumulative translation adjustment			(205,555	)			402,738				(253,821	)			(406,457	)
Comprehensive income		$	959,704			$	1,204,384			$	1,641,155			$	1,261,791

 

See accompanying notes to condensed consolidated financial statements.

 

 

MOCON, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

		Six Months Ended
		June 30,
		2014				2013
Cash flows from operating activities:
Net income		$	1,894,976			$	1,668,248
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense			284,177				260,675
Change in fair value of derivative instrument			92,993				95,053
Gain on disposition of long-term assets			(17,346	)			(44,698	)
Depreciation and amortization			1,268,398				1,157,203
Deferred income taxes			(143,404	)			(501,066	)
Excess tax benefit from employee stock plans			(5,026	)			(19,065	)
Changes in operating assets and liabilities:
Trade accounts receivable, net			1,792,262				(1,289,472	)
Other receivables			(200,167	)			44,376
Inventories			(1,083,782	)			(376,087	)
Prepaid income taxes			(27,340	)			(222,501	)
Prepaid expenses, other			61,852				(52,585	)
Accounts payable			(685,522	)			535,795
Compensation and related expenses			(226,313	)			(244,823	)
Other accrued expenses			(4,306	)			42,775
Accrued product warranties			(103,600	)			1,556
Accrued income taxes			171,214				318,831
Deferred revenue			822,472				462,373
Net cash provided by operating activities			3,891,538				1,836,588
Cash flows from investing activities:
Proceeds from maturities of marketable securities			205,000				3,290,278
Purchases of property, plant and equipment			(831,938	)			(1,056,502	)
Proceeds from sale of property and equipment			55,923				115,898
Cash paid for patents and other intangible assets			(143,842	)			(417,417	)
Other			(1,497	)			(1,506	)
Net cash provided by (used in) investing activities			(716,354	)			1,930,751
Cash flows from financing activities:
Proceeds from the revolving lines of credit			12,885,854				3,724,773
Payments on the revolving lines of credit			(12,298,923	)			(4,628,237	)
Payments on notes payable and seller financed note payable			(1,349,248	)			(1,316,669	)
Proceeds from the exercise of stock options			179,508				246,617
Excess tax benefit from employee stock plans			5,026				19,065
Dividends paid			(1,242,222	)			(1,187,957	)
Net cash used in financing activities			(1,820,005	)			(3,142,408	)
Effect of exchange rate changes on cash and cash equivalents			(34,746	)			(115,625	)
Net increase in cash and cash equivalents			1,320,433				509,306
Cash and cash equivalents:
Beginning of period			4,132,953				2,415,416
End of period		$	5,453,386			$	2,924,722
Supplemental disclosures of cash flow information:
Cash paid during the period for income taxes		$	800,413			$	717,570
Cash paid during the period for interest		$	113,305			$	169,839
Supplemental schedule of noncash investing and financing activities:
Dividends accrued		$	622,856			$	610,251
Purchases of prepaid expenses, fixed assets and intangibles in accounts payable		$	238,664			$	86,068

 

See accompanying notes to condensed consolidated financial statements.

 

 

MOCON, INC. AND SUBSIDIARIES

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD ENDED JUNE 30, 2014

(Unaudited)

 

Note 1 – Condensed Consolidated Financial Statements

 

The condensed consolidated balance sheets as of June 30, 2014, the condensed consolidated statements of income and comprehensive income, for the three and six-month periods ended June 30, 2014 and 2013 and the condensed consolidated statements of cash flows for the six-month periods ended June 30, 2014 and 2013 have been prepared in accordance with accounting principles generally accepted in the United States of America. These interim unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to fairly present the financial position, results of operations and cash flows at June 30, 2014, and for all periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.

 

The results of operations for the three and six-month periods ended June 30, 2014 are not necessarily indicative of operating results for the full year. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, previously filed with the Securities and Exchange Commission.

 

MOCON Inc. and its subsidiaries (collectively, the Company), develops, manufacturers and markets measurement, analytical and monitoring instruments, and provides consulting services for customers in the barrier packaging, food, pharmaceutical, consumer products, industrial hygiene, environmental, air quality monitoring, oil and gas exploration and other industries throughout the world.

 

The Company reports its operating segments as Permeation Products and Services (“Permeation”), Package Testing Products and Services (“Package Testing”), and Industrial Analyzer Products and Services and Other (“Industrial Analyzers and Other”) for financial reporting purposes.

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of MOCON, Inc. and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.

 

Recently Issued Accounting Guidance

 

Revenue from Contracts with Customers

 

In May 2014, the Financial Accounting Standards Board issued new accounting requirements for the recognition of revenue from contracts with customers. The requirements of the new standard are effective for annual reporting periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is currently evaluating the impact of this guidance on its results of operations and financial position.

 

 

Note 2 – Inventories

 

Inventories consist of the following:

 

		June 30,				December 31,
		2014				2013
Finished products		$	1,791,334			$	1,638,997
Work-in-process			2,444,272				1,934,493
Raw materials			4,262,412				3,897,207
		$	8,498,018			$	7,470,697

 

Note 3 – Net Income Per Common Share

 

Basic net income per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted net income per common share is computed using the treasury stock method to compute the weighted average common stock outstanding assuming the conversion of potential dilutive common shares.

 

The following table presents a reconciliation of the denominators used in the computation of net income per common share – basic, and net income per common share – diluted, for the three and six-month periods ended June 30, 2014 and 2013:

 

		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014				2013
Weighted shares of common stock outstanding – basic			5,655,146				5,537,677				5,648,025				5,529,430
Dilutive impact of share-based awards			119,602				134,168				122,182				139,586
Weighted shares of common stock outstanding – diluted			5,774,748				5,671,845				5,770,207				5,669,016

  

Outstanding stock options totaling 116,550 for the three-month period ended June 30, 2014 and 256,375 for the three and six-month periods ended June 30, 2013 were excluded from the net income per common share calculation because the shares would be anti-dilutive.

 

Note 4 – Goodwill and Intangible Assets

 

The changes in the carrying amount of goodwill for the six-month period ended June 30, 2014 were as follows:

 

		Package								Industrial
		Testing				Permeation				Analyzers & Other				Total
Balance as of December 31, 2013		$	6,196,570			$	2,227,979			$	609,930			$	9,034,479
Foreign currency translation			(47,183	)			(16,563	)			-				(63,746	)
Balance as of June 30, 2014		$	6,149,387			$	2,211,416			$	609,930			$	8,970,733

 

The Company tests goodwill for impairment annually at the reporting unit level using a fair value approach. The Company will perform its annual impairment test for goodwill in the fourth quarter.

 

 

Other intangible assets (all of which are being amortized except projects in process) are as follows:

 

 

 

		As of June 30, 2014
						Accumulated
		Cost				Amortization				Net
Patents		$	1,680,720			$	(392,970	)		$	1,287,750
Trademarks and trade names			4,094,622				(598,487	)			3,496,135
Developed technology			7,667,700				(1,916,925	)			5,750,775
Customer relationships			896,700				(224,175	)			672,525
Internally developed software			934,792				-				934,792
Other intangibles			255,118				(72,046	)			183,072
		$	15,529,652			$	(3,204,603	)		$	12,325,049

 

		As of December 31, 2013
						Accumulated
		Cost				Amortization				Net
Patents		$	1,624,590			$	(408,656	)		$	1,215,934
Trademarks and trade names			4,121,170				(495,897	)			3,625,273
Developed technology			7,730,550				(1,503,163	)			6,227,387
Customer relationships			904,050				(175,787	)			728,263
Internally developed software			716,800				-				716,800
Other intangibles			245,118				(40,572	)			204,546
		$	15,342,278			$	(2,624,075	)		$	12,718,203

 

 

Total amortization expense for the three-month periods ended June 30, 2014 and 2013 was $319,770 and $293,548, respectively and $638,753 and $582,302, respectively, for the six-month periods ended June 30, 2014 and 2013. Projects in process are not amortized until the patent or trademark is granted by the regulatory agency or the asset is ready for use. Estimated amortization expense for the remainder of 2014 and each of the four succeeding fiscal years and thereafter based on the intangible assets as of June 30, 2014 is as follows:

 

 

		Estimated Expense
2014		$	633,525
2015			1,270,031
2016			1,253,430
2017			1,221,105
2018			1,190,337
2019 & Thereafter			5,080,326
		$	10,648,754

   

 

Note 5 – Accumulated Other Comprehensive Income (Loss)

 

Adjustments to accumulated other comprehensive income (loss) consist of the following:

 

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2014				2013				2014				2013
Beginning balance		$	564,759			$	(1,436,489	)		$	613,025			$	(627,294	)
Foreign currency translation adjustments			(205,555	)			402,738				(253,821	)			(406,457	)
Amounts reclassified to earnings			--				--				--				--
Accumulated other comprehensive income (loss)		$	359,204			$	(1,033,751	)		$	359,204			$	(1,033,751	)

 

 

 

Note 6 – Investment in Affiliated Company

 

In January 2010, the Company acquired a minority equity ownership interest in Luxcel Biosciences Limited (Luxcel) based in Cork, Ireland. The investment of €2.5 million (approximately $3.6 million) amounted to a 16.9% equity interest in Luxcel. The Company has evaluated the cost versus equity method of accounting for its investment in Luxcel and determined that it does not have the ability to exercise significant influence over the operating and financial policies of Luxcel and, therefore, accounts for its investment on a cost basis. The investment in Luxcel is carried on our condensed consolidated balance sheets at the original purchase price, adjusted for currency fluctuations. The Company believes that it is not feasible to readily estimate the fair value of its investment in Luxcel. Information related to future cash flows of Luxcel is not readily available as the entity is a start-up research and development company and future cash flows are highly dependent on their ability to obtain additional funding, gain acceptance of its products in the marketplace, and obtain regulatory approvals.

 

During 2013, the Company paid $200,000 for two license and distribution agreements with Luxcel which grants the Company access to proprietary technology on an exclusive basis for a period of four years. In addition, the terms of the distribution agreement allow the Company to contract for future research and development services. These services are purchased through upfront payments tied to specific work orders and are refundable if the work is cancelled,  excluding amounts incurred for work completed up to the cancellation date.  At June 30, 2014, the Company has recognized a prepaid expense of $257,000 on the Condensed Consolidated Balance Sheet as a result of the Company contracting for future services to be provided by Luxcel.                                               

 

As part of the relationship with Luxcel, the Company purchases sensors which accompany our instruments for sale to an end user and we are required to pay a royalty to Luxcel on the sale of such instruments.

 

Note 7 – Warranty

 

The Company provides a warranty for most of its products. Warranties are for periods ranging from ninety days to one year, and cover parts and labor for non-maintenance repairs at our locations. Operator abuse, improper use, alteration, damage resulting from accident, or failure to follow manufacturer’s directions are excluded from warranty coverage.

 

Warranty expense is accrued at the time of sale based on historical claims experience. Warranty reserves are also accrued for special rework campaigns for known major product modifications. The Company also offers extended warranty service contracts for select products when the factory warranty period expires.

  

 

Warranty provisions and claims for the three and six-month periods ended June 30, 2014 and 2013 were as follows:

 

 

		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014				2013
Beginning balance		$	322,328			$	245,269			$	335,533			$	240,621
Warranty provisions			(19,628	)			43,611				50,986				166,500
Warranty claims			(72,013	)			(48,330	)			(155,832	)			(166,571	)
Ending balance		$	230,687			$	240,550			$	230,687			$	240,550

  

 

Note 8 – Debt

 

Notes payable consists of the following:

		June 30, 2014				December 31, 2013
Note payable to bank, with interest at 3.46%, payable in monthly principal installments of $72,917 plus interest through March 28, 2016, collateralized by all the assets of the Company except the Dansensor stock.		$	1,604,158			$	2,041,660
Seller financed note payable (Seller Note), with interest at 3.46%, payable in semi-annual payments of principal and interest totaling $891,000 beginning October 2, 2012 through April 2, 2015, collateralized by 65% of the outstanding stock of Dansensor.			1,010,416				1,914,941
Capital leases			40,342				47,926
Total notes payable		$	2,654,916			$	4,004,527
Less current portion of notes payable			1,892,812				2,697,678
Total long-term notes payable		$	762,104			$	1,306,849

 

In the U.S., the Company has a $6.0 million secured revolving line of credit with a maturity date of March 28, 2016. Interest is charged monthly at one-month LIBOR plus 1.75 basis points which totaled 2.00% at June 30, 2014 and December 31, 2013. The line of credit is secured by the assets of the Company with the exception of the Dansensor stock, and there was $4,625,000 outstanding at June 30, 2014. In Denmark, the Company has a DKK 10,000,000 (approximately $1.83 million) available line of credit of which DKK 1,222,691 (approximately $223,752) was outstanding as of June 30, 2014. Outstanding borrowings on this line of credit are charged interest at 4.35% per year.

 

The Company is subject to various financial and restrictive covenants in the bank Credit Agreement, including maintaining certain financial ratios and limits on incurring additional indebtedness, making capital and lease expenditures and making share repurchases. As of June 30, 2014, the Company was in compliance with these various covenants and expects to remain in compliance throughout 2014.

 

The carrying value of the Seller Note is adjusted for foreign currency translation at each reporting period and the change in value is included in other expense in the condensed consolidated statements of income.

 

 

As of June 30, 2014, the future minimum principal payments of the notes payable for the remainder of 2014 and each of the four succeeding fiscal years and thereafter are as follows:

 

2014		$	1,349,228
2015			996,577
2016			306,135
2017			2,976
		$	2,654,916

 

Note 9 – Income Taxes

 

The Company's provision for income tax expense was 31.2% and 2.6% of income before income taxes for the second quarters ended June 30, 2014 and 2013, respectively. The rate in the second quarter 2014 was lower than the statutory rate due primarily to the effect of foreign operations where tax rates tend to be lower as well as the domestic manufacturing deduction. The rate in the second quarter 2013 was positively impacted by tax law changes related to enacted legislation which lowered the corporate income tax rates in Denmark. The impact of this change was a reduction of a deferred tax liability, which was recorded as a discrete adjustment to income tax expense in that quarter in the amount of $258,000. The Company's effective tax rate for the second quarter 2013 would have been 33.9% if this one-time adjustment had not been made.

 

For the six-month period ended June 30, 2014, the Company's income tax expense was 31.2% of income before income taxes compared to 15.5% for the same period of 2013. The rate for the first six months of 2014 was lower than the statutory rate due primarily to the effect our foreign operations and the domestic manufacturing deduction. The rate for the first six months of 2013 was positively impacted by the tax law changes noted above as well as the domestic tax law change related to research and development credits which was effective in the first quarter 2013. The Company's effective tax rate for the six months ended June 30, 2013 would have been 28.5% if the adjustment for the change in the Danish tax rates had not been made.

 

As of June 30, 2014 and December 31, 2013, the liability for gross unrecognized tax benefits was $320,000 and $304,000, respectively. Changes in gross unrecognized tax benefits during the six-months ended June 30, 2014 primarily consisted of an increase for tax positions taken in the current year. It is expected that the amount of unrecognized tax benefits for positions which the Company has identified will not materially change in the next twelve months.

 

Note 10 – Stock-Based Compensation

 

As of June 30, 2014, the Company has reserved 138,489 shares of common stock for options and other stock-based incentive awards that are still available for grant under our 2006 stock incentive plan, and 710,800 shares for options that have been granted under either the 2006 stock incentive plan or the 1998 stock option plan but have not yet been exercised. The Company issues new shares of common stock upon exercise of stock options. There were options for an aggregate of 146,400 shares granted in the first six months of 2014.

 

Amounts recognized in the condensed consolidated financial statements related to stock-based compensation are as follows:

 

		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014				2013
Total cost of stock-based compensation		$	141,570			$	128,567			$	284,177			$	260,675
Amount of income tax benefit recognized in earnings			(21,790	)			(21,799	)			(42,964	)			(43,803	)
Amount charged against net income		$	119,780			$	106,768			$	241,213			$	216,872

 

 

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model (Black-Scholes). The Company uses historical data to estimate the expected price volatility, expected option life and expected forfeiture rate. The Company bases its estimate of expected volatility for awards granted on daily historical trading data of its common stock for a period equivalent to the expected term of the award.

 

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option. The Company estimates the expected term consistent with historical exercise and cancellation activity of its previous share-based grants with a seven year contractual term. Forfeitures are based on historical experience. The dividend yield is calculated based upon the dividend payments made during the prior four quarters as a percent of the average stock price for that period.

 

A summary of the option activity for the first six months of 2014 is as follows:

 

		Number of Shares				Weighted Average Exercise Price per Share				Weighted Average Remaining Contractual Term				Aggregate Intrinsic Value
Outstanding at December 31, 2013			622,300			$	12.34				3.7			$	2,174,673
Options granted			146,400			$	15.86				6.5
Options cancelled/expired			(3,800	)		$	15.46				--
Options exercised			(54,100	)		$	9.94				--
Outstanding at June 30, 2014			710,800			$	13.23				4.0			$	1,860,165
Exercisable at June 30, 2014			523,406			$	12.46				3.4			$	1,771,538

 

The total intrinsic value of options exercised was $108,326 and $136,582 during the three-month periods ended June 30, 2014 and 2013, respectively, and $335,940 and $173,288 during the six-month periods ended June 30, 2014 and 2013, respectively.

 

A summary of the status of the Company's unvested option shares as of June 30, 2014 is as follows:

 

		Number of Shares				Weighted Average Grant Date Fair Value
Unvested at December 31, 2013			79,225			$	3.98
Options granted			146,400			$	4.13
Options cancelled			(3,225	)		$	3.89
Options vested			(35,006	)		$	4.39
Unvested at June 30, 2014			187,394			$	4.02

 

As of June 30, 2014, there was $623,383 of total unrecognized compensation cost related to unvested stock-based compensation granted under the Company's plans. That cost is expected to be recognized over a weighted-average period of 1.3 years. The total fair value of option shares vested during the three-month periods ended June 30, 2014 and 2013 was $76,851 and $71,757, respectively, and $153,676 and $143,513 during the six-month periods ended June 30, 2014 and 2013, respectively.

 

 

Note 11 – Derivative Instrument

 

As of June 30, 2014, the Company has one foreign currency contract outstanding with a notional amount of 6.1 million Danish krone (DKK) or $1.1 million. The foreign currency contract was purchased to economically hedge the foreign currency fluctuation from the remeasurement of the third party seller financed note payable (Seller Note) which is denominated in DKK (Note 8). The foreign currency contract has various settlement dates that coincide with the Company’s Seller Note payment schedule. The term of the foreign currency contract coincides with the maturity of the Seller Note which is April 2, 2015. The fair value of the contract resulted in an asset of approximately $90,000 at June 30, 2014, as compared to approximately $183,100 at December 31, 2013. The decrease in the fair value of the contract totaling approximately $89,000 for the three-month period ended June 30, 2014 and the decrease of $93,000 for the six-month period ended June 30, 2014 were recognized in other expense in the condensed consolidated statements of income. Substantially all of this expense is offset by the remeasurement of the Seller Note to reflect the change in foreign currency rates.

 

Note 12 – Fair Value Measurements

 

The Company determines the fair market value of its derivative contract based on the fair value hierarchy, described below, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels within the fair value hierarchy that may be used to measure fair value:

 

Level 1: Values based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities.

 

Level 2: Values based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuation techniques for which all significant assumptions are observable in the market.

 

Level 3: Values generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Company's estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques include use of option pricing models, discounted cash flow models and similar techniques.

 

The following table provides information on those assets that are measured at fair value on a recurring basis:

  

 

						Fair Value Measurements at the end of the Reporting Period Using
Assets:		Carrying value				Significant Other Observable Inputs (Level 2)
June 30, 2014:
Foreign currency contract		$	90,144			$	90,144
December 31, 2013:
Foreign currency contract		$	183,137			$	183,137

 

 

The fair value of the foreign currency contract is determined based on observable market transactions of spot currency rates and forward currency prices. The carrying values of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, revolving lines of credit and current maturities of notes payable approximate fair value due to their short-term maturity. The fair value of the long-term debt, measured as Level 2 financial instruments, is estimated based on anticipated interest rates which management believes would currently be available to the Company for similar issues of debt, taking into account the current credit risk of the Company and other market factors. The Company believes the carrying value of the long-term debt approximates fair value.

 

Note 13 – Business Segments

 

 

The Company has four operating segments and three reportable segments, structured by differences in products and services, that are regularly reviewed by the Company’s chief operating decision maker to make decisions about allocating resources and assessing segment performance. The segment performance is evaluated at segment operating income which is defined as gross profit less selling, general and administrative expenses and research and development expenses. General corporate expenses, including costs associated with various support functions such as human resources, information technology, finance and accounting, and general and administrative costs, are allocated to the reportable segments. The Company’s four operating segments have been aggregated into three reportable segments based on the authoritative guidance. The Company aggregated its Other Products and Services operating segment into the Industrial Analyzer Products and Services segment based on minimal business activity and materiality.

 

The Permeation segment includes instruments and services that measure the rate at which various gases and vapors permeate through a variety of materials. The Package Testing segment provides customers with the ability to assess package performance, shelf-life, package improvement, cost reduction, sustainability and product safety using Modified Atmosphere Packaging and other technologies. The Industrial Analyzers and Other segment includes advanced gas analysis and monitoring instrumentation used in applications such as oil and gas exploration, beverage and specialty gas analysis, industrial hygiene and safety, food safety and environmental air monitoring.

 

The accounting policies of the reportable segments are the same as those described in Note 1 to the Consolidated Financial Statements found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Intersegment sales for the three and six month periods ended June 30, 2014 and 2013 were insignificant.

 

 

Financial information by reportable segment for the three and six-month periods ended June 30, 2014 and 2013 is as follows:

 

		Three Months Ended June 30, 2014								Six Months Ended June 30, 2014
		Trade Revenue				Segment Operating Income				Trade Revenue				Segment Operating Income
Permeation		$	5,043,897			$	661,134			$	10,892,396			$	1,674,731
Package Testing			7,353,969				678,486				13,978,436				729,038
Industrial Analyzers and Other			3,176,657				446,254				6,016,839				502,736
Total		$	15,574,523			$	1,785,874			$	30,887,671			$	2,906,505

 

 

 

		Three Months Ended June 30, 2013								Six Months Ended June 30, 2013
		Trade Revenue				Segment Operating Income (Loss)				Trade Revenue				Segment Operating Income
Permeation		$	5,150,886			$	863,123			$	10,116,828			$	1,352,966
Package Testing			6,035,986				(20,688	)			12,647,618				509,164
Industrial Analyzers and Other			2,501,143				66,785				5,370,747				302,438
Total		$	13,688,015			$	909,220			$	28,135,193			$	2,164,568

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This Management’s Discussion and Analysis provides material historical and prospective disclosures intended to enable investors and other users to assess our financial condition and results of operations. Statements that are not historical are forward-looking and involve risks and uncertainties discussed below under the caption “Forward-Looking Statements.” The following discussion of the results of operations and financial condition of MOCON should be read in conjunction with our consolidated financial statements and the related notes thereto included elsewhere in this report.

 

Overview

 

Description of Business

 

MOCON, Inc. designs, manufactures, markets and services products and provides consulting and testing services primarily in the measurement and analytical instrument and services markets. Our products include instruments that detect, measure and monitor gases and chemical compounds. We continually seek growth opportunities through technological and product improvement, by developing new products, and by acquiring new companies, new product lines, or rights to technologies.

 

We have two primary operating locations in the United States – Minnesota and Colorado – and we have foreign offices and laboratories in Denmark, Germany, France, Italy, Spain and China. We use a mix of a direct sales force and independent sales representatives to market our products and services in the United States, Canada, Europe and China, and we use a network of independent sales representatives to market and service our products and services in most other foreign countries.

 

Historically, a significant portion of our sales has come from international customers. The international portion of our consolidated sales has increased from recent historical trends since the acquisition of Dansensor as the principal portion of their sales are to European customers.

 

Our ongoing plans for growth include continued substantial funding for research and development to drive new product development, together with strategic acquisitions and investments where appropriate.

 

Products and Services

 

Permeation Products and Services

 

Our permeation products consist of systems and services that measure the rate at which various gases and vapors transmit through a variety of materials. These products perform measurements under precise temperature, pressure and relative humidity conditions. The principal market for these products consists of manufacturers of packaging materials, including manufacturers of papers, plastic films, coatings and containers and the users of such packaging materials, such as companies in the food, beverage, pharmaceutical and consumer product industries. Other customers include manufacturers of flat panel displays, solar panels, electronics, and many other sophisticated materials.

 

We also provide certain laboratory testing services to companies that have a need for permeation data. These services consist primarily of testing film and package permeation for companies that:

 

●

wish to outsource their testing needs to us;

 

●

are interested in evaluating our instrumentation prior to purchase; or

 

●

have purchased our products but have a need for additional capacity.

 

 

Permeation instruments that we currently manufacture include OX-TRAN^® systems for oxygen transmission rates, PERMATRAN-W^® systems for water vapor transmission rates, and PERMATRAN-C^® systems for carbon dioxide transmission rates. Our AQUATRAN^® ultra-high sensitivity, trace moisture permeation analyzer has been increasingly accepted as the standard test instrument of choice in the flat panel, solar cell and electronics industries. Our systems are available in a wide range of options for our customers, including high or low throughput, price, sensitivity and ease of use. They are primarily marketed to research and development departments, as well as production and quality assurance groups. During the second quarter 2014, the Company began shipping the OX-TRAN Model 2/22 for oxygen transmission measurement, the first in our new series of technologically-advanced permeation instruments.

 

Package Testing Products and Services

 

We manufacture and sell three primary products in this group: headspace analyzers, leak detection equipment and gas mixers. Our headspace analyzer products are used to analyze the amount and type of gas present in the headspace of flexible and rigid packages, as applied to gas flushing in modified or controlled atmosphere packaging. The principal market for these products consists of packagers of foods, beverages and pharmaceuticals. Our headspace analyzer products include the PAC CHECK^®, CheckMate^TM and CheckPoint^TM series of off-line headspace analyzers and the MAP Check 3™ series of on-line analyzers. for continuous and intermittent monitoring of modified atmosphere packaging (MAP) and other gas flushing operations. Our leak detection products detect leaks in sterile medical trays, food pouches, blister packs and a wide range of other sealed packages. We currently manufacture three types of leak detection instruments. The first type is a non-destructive leak detector that senses small amounts of carbon dioxide escaping from a package or tray. The second type of instrument detects leaks and checks for seal integrity by applying and measuring pressure within a package. The third type pulls a vacuum on a package and looks for vacuum or gas flow changes. The principal markets for these products are packagers of sterile medical items, pharmaceuticals and food products. Our leak detection products include the LeakMatic II^TM and LeakPointer II^TM series of instruments.

 

Our gas mixers are used in the food production environment to assure that the package has been properly flushed with the correct mixture of gases. Our gas mixer products include the MAP Mix Provectus and MAP Mix 9001 on-line instruments.

 

Industrial Analyzer Products and Services and Other

 

Sales of our gas analyzers, sensors and detector products comprise the majority of sales in this segment. We offer advanced gas analysis and monitoring instrumentation used in applications such as oil and gas exploration, process gas analysis, industrial hygiene and safety, environmental air monitoring and indoor air quality.

 

In this group, we manufacture and sell two types of gas analyzer instruments: gas chromatographs (GCs) and total hydrocarbon analyzers (THAs). These instruments are typically installed in fixed locations at the monitoring sites and perform their functions of detecting and measuring various hydrocarbons continually or at regular intervals. We also make gas sensors and detectors which are sold to original equipment manufacturers (OEMs) of mobile gas safety equipment.

 

Our industrial analyzer products, sensors and detectors are for use in industrial hygiene (detection of hazardous gases in the workplace), hydrocarbon gas analysis for oil and gas exploration, contaminant detection in the manufacture of specialty gases, and environmental monitoring (tracking the release, or the presence, of toxic substances). Our newest GC offering measures trace levels of contaminants in beverage grade carbon dioxide which is used to carbonate soft drinks, beer and water.

 

We market some of these products under the names BEVALERT^®, PETROALERT^®, and piD-TECH^®.

 

 

Microbial Detection Products

 

Our microbial detection products are designed to rapidly detect microbial growth in food and beverage samples. Using the total viable count (TVC) method, our GreenLight^® series of instruments perform rapid and precise measurements to determine the presence or absence of aerobic bacteria in food products or ingredients. There are two models of the GreenLight product line currently available.

 

Results of Operations

 

The following table sets forth the relationship between various components of our results of operations, stated as a percent of sales, for the three and six-month periods ended June 30, 2014 and 2013:

 

 

		Three Months Ended June 30								Six Months Ended June 30,
		2014				2013				2014				2013
Sales			100.0				100.0				100.0				100.0
Cost of sales			44.0				44.1				44.6				44.4
Gross profit			56.0				55.9				55.4				55.6
Selling, general and administrative expenses			38.2				41.4				39.2				40.1
Research and development expenses			6.3				7.9				6.8				7.8
Operating income			11.5				6.6				9.4				7.7
Other income (expense), net			(0.6	)			(0.6	)			(0.5	)			(0.7	)
Income before income taxes			10.9				6.0				8.9				7.0
Income taxes			3.4				0.1				2.8				1.1
Net income			7.5				5.9				6.1				5.9

 

 

Comparison of Financial Results for the Three and Six-Month Periods Ended June 30, 2014 and 2013

 

Sales

 

Total consolidated sales for the three-month period ended June 30, 2014 were $15,574,000, up 13.8% compared to $13,688,000 for the same period in 2013. The growth for the quarter was attributable primarily to our Industrial Analyzer and Other segment which recorded a 27% increase in revenues, and experienced growth in all major product lines. In addition, sales in our Package Testing segment increased in the current year second quarter by 22%. Sales in our Permeation segment were down 2% which was due primarily to weak domestic demand for services and instruments.

 

Sales for the six-month period ended June 30, 2014 were $30,887,000, up 9.8% compared to $28,135,000 for the same period in 2013, as all three segments reported increased revenues. Sales in our Permeation segment rose 8%, due primarily to a significant increase in international shipments. Sales in our Package Testing segment were up 11%, partially due to sales of headspace analyzers which were held up at the end of 2013 due to the supplier sensor issue we've previously disclosed. Sales in our Industrial Analyzer and Other segment were up 13% in the current period, with growth in all major product lines, and led by shipments of sensors and OEM detectors.

 

Total consolidated sales to foreign customers increased 20% in the current quarter compared to the same quarter last year and accounted for 72% and 69% of total consolidated sales for the quarters ended June 30, 2014 and 2013, respectively. Sales to foreign customers for the six-months periods ended June 30, 2014 and 2013, respectively, amounted to 72% and 67% of total consolidated sales, and were up 19% in the current period.

 

 

The following table summarizes total sales by reporting segments for the three and six-month periods ended June 30, 2014 and 2013:

  

 

		Three Months Ended June 30								Six Months Ended June 30,
		2014				2013				2014				2013
Permeation		$	5,043,897			$	5,150,886			$	10,892,396			$	10,116,828
Package Testing			7,353,969				6,035,986				13,978,436				12,647,618
Industrial Analyzers and Other			3,176,657				2,501,143				6,016,839				5,370,747
Total		$	15,574,523			$	13,688,015			$	30,887,671			$	28,135,193

 

 

The following table sets forth the relationship between various components of domestic and foreign sales for the three and six-month periods ended June 30, 2014 and 2013:

 

 

		Three Months Ended June 30								Six Months Ended June 30,
		2014				2013				2014				2013
Domestic Sales		$	4,311,607			$	4,279,529			$	8,497,602			$	9,334,599
Foreign Sales:
Europe			6,693,002				5,946,696				12,995,703				12,136,604
Asia			3,750,461				2,809,252				7,374,997				5,035,597
Other			819,453				652,538				2,019,369				1,628,393
Total Foreign Sales			11,262,916				9,408,486				22,390,069				18,800,594
		$	15,574,523			$	13,688,015			$	30,887,671			$	28,135,193

 

 

Permeation Testing Products and Services – Sales in our Permeation segment declined 2% for the three months ended June 30, 2014 compared to the same period in the prior year, and accounted for 33% and 38% of our consolidated second quarter sales in 2014 and 2013, respectively. The slight decline in the current period is due to a continued weak domestic market for both instruments and consulting and testing services. Offsetting most of the domestic decline, international sales rose 9% in the current quarter, as Europe recorded impressive growth. In particular, Southern Europe which had been depressed for the last two to three years, showed signs of economic recovery. Foreign sales comprised 71% of the shipments in this segment in the second quarter 2014, compared to 64% from the same period in the prior year.

 

During the second quarter 2014, the Company began shipping the OX-TRAN™ Model 2/22, the new generation of oxygen permeation instruments, but was not a significant contributor to revenue in the current period.

 

Sales in our Permeation segment increased 8% for the first six months ended June 30, 2014 compared to the same period in the prior year, and accounted for 35% and 36% of our consolidated first six months sales in 2014 and 2013, respectively. Foreign sales comprised 71% of the sales in this segment in the first half of 2014, compared to 63% from the same period in the prior year, and increased 23%. This increase more than offset a 17% decline in domestic sales for the six month period.

 

 

Package Testing Products and Services – Sales in our Package Testing segment increased 22% for the three months ended June 30, 2014 compared to the same period in the prior year, and accounted for 47% and 44% of our consolidated second quarter sales in 2014 and 2013, respectively. Sales of headspace analyzers were higher than expected and improved over the prior year second quarter. The sensor issue that was noted in the prior two quarters has been rectified and new instruments were shipped in the current quarter. Sales of leak detection instruments also were higher than expected and significantly improved over the prior year.

 

Sales in our Package Testing segment, which accounted for 45% of our consolidated sales during the first six months in 2014 and 2013, increased 11% in the current period compared to the same period in 2013. Improved sales of headspace analyzers, leak detectors and online analyzers and mixers all contributed to the current year growth. Sales to foreign destinations comprised 79% and 78% of total sales in this segment for the six months ended June 30, 2014 and 2013, respectively.

 

Industrial Analyzer Products and Services and Other – Sales in our Industrial Analyzers and Other segment, which accounted for 20% and 18% of our consolidated second quarter sales in 2014 and 2013, respectively, increased 27% during the second quarter 2014 compared to the same period in 2013. Sales in this segment are comprised mainly of instruments and services provided by our Baseline subsidiary. Sales of instruments to the oil and gas exploration and environmental monitoring markets, as well as sales of OEM sensors and detectors for worker safety applications, accounted for the majority of the increase.

 

Sales in our Industrial Analyzers and Other segment, which accounted for 20% and 19% of our consolidated sales for the first six months of 2014 and 2013, respectively, increased 13% during the first six months of 2014 compared to the same period in 2013. Sales of OEM sensors and detectors for worker safety applications, accounted for the majority of the increase. Sales of gas chromatographs and hydrocarbon analyzers also improved as demand in the oil and gas drilling and environmental monitoring markets continues to be strong.

 

Gross Profit

 

The consolidated gross profit margin was 56% for both the second quarters ended June 30, 2014 and 2013. The gross margin in the Permeation segment was one percentage point lower in the current quarter compared to last year due primarily to lower domestic permeation instrument sales and lower consulting revenue where costs are relatively fixed. The gross margin in the Package Testing segment increased by approximately two percentage points in the current quarter compared to last year due to higher sales of headspace analyzers and better capacity utilization as a result of increased production. The gross margin in the Industrial Analyzer and Other segment increased by one percentage point in the current quarter compared to the prior year quarter. The increase was due primarily to a greater percentage increase of higher margin instrument sales as compared to the increase in sensor and detector sales.

 

For the six months ended June 30, 2014 and 2013, the consolidated gross profit margins were 55% and 56%, respectively. The year-to-date gross margin in the Permeation segment improved by one percentage point in the current period compared to the same period last year as a result of increased sales of higher margin instruments combined with slightly lower consulting revenue. The year-to-date gross margin in the Package Testing segment was consistent at 49% in both six-month periods. The year-to-date gross margin in the Industrial Analyzer and Other segment was lower by two percentage points in the current six-month period as the increase in sales of sensors and detectors was greater than the increase in instrument shipments.

 

The overall gross profit margin varies from quarter to quarter depending on product mix and other factors.

 

 

Selling, General and Administrative Expenses

 

Selling, general and administrative (SG&A) expenses were $5,947,000, or 38% of consolidated sales, in the three-month period ended June 30, 2014, compared to $5,668,000, or 41% of consolidated sales, in the same period of 2013. The dollar increase in the current quarter was primarily related to increased commissions resulting from higher sales, increased headcount in the sales and marketing area, and higher incentive compensation due to improved operating results. The current period expense is within our expected range of 35% to 38% of sales. 

 

SG&A expenses were $12,090,000, or 39% of consolidated sales, in the six-month period ended June 30, 2014, compared to $11,271,000, or 40% of consolidated sales, in the same period of 2013. The dollar increase in the current six-month period was primarily related to higher professional fees for audit and SOX compliance consulting, increased commissions, and higher compensation related expenses resulting from increased headcount and incentive compensation.

 

Research and Development Expenses

 

Research and development (R&D) expenses were $989,000 in the second quarter 2014, compared to $1,080,000 in the same period of 2013. The current period expense is slightly below our planned level of spending, but within our expected range which we project to be between 6% to 8% of sales each year.

 

R&D expenses were $2,114,000 in the first six months of 2014, compared to $2,198,000 in the same period of 2013. The current period expense is slightly below our planned level of spending, but within our expected range.

 

Other Income (Expense)

 

Other income (expense) for the three and six-month periods ended June 30, 2014 and 2013 was as follows:

 

 

 

		Three Months Ended June 30								Six Months Ended June 30,
		2014				2013				2014				2013
Interest income		$	1,247			$	10,995			$	2,480			$	14,809
Interest expense			(47,209	)			(70,370	)			(103,848	)			(160,070	)
Foreign currency exchange loss			(47,392	)			(28,110	)			(48,814	)			(48,484	)
Other			-				1,182				-				3,063
Total other income (expense)		$	(93,354	)		$	(86,303	)		$	(150,182	)		$	(190,682	)

 

 

Income Tax Expense 

 

Our provision for income tax expense was 31.2% and 2.6% of income before income taxes for the second quarters ended June 30, 2014 and 2013, respectively. The rate in the second quarter 2014 was lower than the statutory rate due primarily to the effect of foreign operations where tax rates tend to be lower as well as the domestic manufacturing deduction. The rate in the second quarter 2013 was positively impacted by tax law changes related to enacted legislation which lowered the corporate income tax rates in Denmark. The impact of this change was a reduction of a deferred tax liability, which was recorded as a discrete adjustment to income tax expense in that quarter in the amount of $258,000. Our effective tax rate for the second quarter 2013 would have been 33.9% if this one-time adjustment had not been made.

 

 

For the six-month period ended June 30, 2014, our income tax expense was 31.2% of income before income taxes compared to 15.5% for the same period of 2013. The rate for the first six months of 2014 was lower than the statutory rate due primarily to the effect of our foreign operations and the domestic manufacturing deduction. The rate for the first six months of 2013 was positively impacted by the tax law changes noted above as well as the domestic tax law change related to research and development credits which was effective in the first quarter 2013. Our effective tax rate for the six months ended June 30, 2013 would have been 28.5% if the adjustment for the change in the Danish tax rates had not been made.

 

Based on current projected annual operating results and current income tax rates, we expect the effective tax rate for the remainder of 2014 to be consistent with our experience in the first six months. This rate fluctuates over time based on the income tax rates in the various jurisdictions in which we operate, and also the level of profits in those jurisdictions.

 

Net Income

 

Net income was $1,165,000 in the second quarter 2014, compared to a net income of $802,000 in the second quarter 2013. Diluted net income per share was $0.20 and $0.14 in the second quarters of 2014 and 2013, respectively. For the six months ended June 30, 2014, net income was $1,895,000, or $0.33 per diluted share, compared to $1,688,000, or $0.29 per diluted share in the prior year.

 

Liquidity and Capital Resources

 

Total cash, cash equivalents and marketable securities increased $1,115,000 to $5,453,000 during the six-month period ended June 30, 2014, compared to $4,338,000 at December 31, 2013. Included in the June 30, 2014 total, was $4,430,000 held outside of the United States. The year-to-date increase in cash, cash equivalents and marketable securities was primarily due to cash provided from operations of $3,892,000, partially offset by net pay-downs on our revolving lines of credit and term debt totaling $762,000, dividend payments of $1,242,000 and capital expenditures of $832,000. At June 30, 2014, we had $4.8 million outstanding on the revolving lines of credit compared to $4.3 million at December 31, 2013. The four-year term note is payable in monthly principal installments of $72,917 plus interest at 3.46% per annum. The four-year seller note is payable in semi-annual installments of $891,000, including interest, at 3.46% per annum. The U.S. revolving line of credit accrues interest at 1.75% over the one-month LIBOR rate, which totaled 2.00% at June 30, 2014. The term note and the revolving line of credit related to our U.S. borrowings are due on March 28, 2016, and we are subject to certain financial and restrictive covenants.

 

Our working capital as of June 30, 2014 was $10,867,000, an increase of $232,000 compared to $10,635,000 at December 31, 2013. This increase is primarily related to the increase in cash and cash equivalents, an increase in inventories, and a decrease in current maturities of long-term notes payable, partially offset by a reduction in trade accounts receivable.

 

One of our strategic objectives is, as market and business conditions warrant, to consider acquisitions of, or investments in, businesses, products and/or technologies. If we wish to pursue one or more additional acquisition opportunities, this may require the consent of the Bank under the credit agreement we have executed, and we may need to fund such activities with a portion of our cash balances and debt or equity financing. If we need to raise additional capital, an equity-based or equity-linked financing may be used which could be dilutive to existing shareholders. If we raise additional funds by issuing debt, we may be subject to additional restrictive covenants that could limit our operational flexibility and higher interest expense could dilute earnings per share.

 

 

We may invest a portion of our available cash in highly liquid marketable securities consisting primarily of certificates of deposits, municipal bonds, and money market funds. Our investment policy is to manage these assets to preserve principal, maintain adequate liquidity at all times, and maximize returns subject to investment guidelines we maintain.

 

We believe that a combination of our existing cash and cash equivalents, funds available under the revolving credit facility, and an expected continuation of cash flow from operations, will continue to be adequate to fund our operations and working capital, capital expenditures, required payments on indebtedness and dividend payments. For those international earnings considered to be reinvested indefinitely, we currently have no intention to, and plans do not indicate a need to, repatriate the funds related to those earnings for U.S. operations.

 

Cash Flow

 

Cash Flow from Operating Activities

 

Historically, our primary source of funds has been cash provided by operating activities. In the first six months of 2014, cash provided by operations totaled approximately $3,892,000, due primarily to net income of $1,895,000, non-cash depreciation and amortization of $1,268,000, an increase in deferred revenue of $822,000, and an decrease in trade accounts receivable of $1,792,000. These increases in cash from operating activities were partially offset by a decrease in accounts payable of $686,000, and in increase in inventories of $1,084,000.

 

In the first six months of 2013, cash provided by operations totaled approximately $1,837,000 due primarily to net income of $1,668,000, non-cash depreciation and amortization of $1,157,000, an increase in deferred revenue of $462,000, and an increase in accounts payable of $536,000. These increases in cash from operating activities were partially offset by an increase in trade accounts receivable of $1,289,000, a reduction in deferred income taxes of $501,000, and in increase in inventories of $376,000.

 

Cash Flow from Investing Activities

 

Cash used in investing activities totaled approximately $716,000 in the first six months of 2014 due primarily to the purchase of property, plant and equipment and intangible assets of $975,000, partially offset by the receipt of proceeds from maturities of marketable securities of $205,000.

 

Cash provided from investing activities totaled approximately $1,931,000 in the first six months of 2013 due primarily to the receipt of proceeds from maturities of marketable securities of $3,290,000, partially offset by cash paid for intangible assets and property, plant and equipment additions of $1,474,000.

 

Cash Flow from Financing Activities

 

Cash used in financing activities in the first six months of 2014 totaled approximately $1,820,000 due primarily to a reduction of our term notes payable of $1,349,000, and dividends paid of $1,242,000. These uses of cash were partially offset by the proceeds received from stock option exercises of $180,000 and net proceeds from our revolving line of credit of $587,000.

 

Cash used in financing activities in the first six months of 2013 totaled approximately $3,142,000 due primarily to a reduction of our term notes payable of $1,317,000, a net pay-down on our revolving lines of credit of $903,000, and dividends paid of $1,188,000. These uses of cash were partially offset by the proceeds received from stock option exercises of $247,000.

 

Although we have repurchased shares of our common stock in the past, we currently are not authorized by our Board of Directors to make repurchases of our common stock and are prohibited from doing so under the credit agreement with the Bank unless we obtain the Bank’s approval.

 

 

Contractual Obligations

 

We refer you to our Annual Report on Form 10-K for the year ended December 31, 2013 for a summary of our contractual obligations related to operating leases, purchase obligations and financing arrangements.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements, as defined by the rules and regulations of the SEC, that have or are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. As a result, we are not materially exposed to financing, liquidity, market or credit risk that could arise if we had engaged in these arrangements.

 

Recently Issued Accounting Guidance

 

Revenue from Contracts with Customers

 

In May 2014, the Financial Accounting Standards Board issued new accounting requirements for the recognition of revenue from contracts with customers. The requirements of the new standard are effective for annual reporting periods beginning after December 15, 2016, and interim periods within those annual periods. We are currently evaluating the impact of this guidance on our results of operations and financial position.

 

 

Critical Accounting Policies

 

Our most critical accounting policies, which are those that require significant judgment, include policies related to revenue recognition, allowance for doubtful accounts, accrual for excess and obsolete inventories, recoverability of long-lived assets, goodwill and, income taxes. An in-depth description of these can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Management has not changed the method of calculating and using estimates and assumptions in preparing our condensed consolidated financial statements in accordance with generally accepted accounting principles. There have been no changes in the policies for our accounting estimates for the quarter ended June 30, 2014.

 

Forward-Looking Statements

 

This report contains forward-looking statements that involve future events, our future performance and our future operations and actions.  In some cases you can identify forward-looking statements by the use of words such as “may,” “should,” “anticipate,” “believe,” “expect,” “plan,” “future,” “intend,” “could,” “estimate,” “predict,” “hope,” “potential,” “continue,” or the negative of these terms or other similar expressions. These forward-looking statements are only our predictions and involve numerous assumptions, risks and uncertainties. These forward-looking statements may be contained in the notes to our consolidated financial statements and elsewhere in this report, including under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

 

 

 

Some of the factors known to us that could cause our actual results to differ materially from what we have anticipated in our forward-looking statements are described below.

 

●

Failure to correct material weakness in our internal control over financial reporting;

●

Failure to effectively integrate the operations of Dansensor with ours;

●

Decline in overall economic or business conditions;

●

Ability to meet our debt obligations in a timely manner;

●

The impact of complying with our bank covenants;

●

Impairment of our investment in Luxcel due to adverse operating results as compared to plan;

●

Increases in prices for raw materials;

●

Risks inherent in operating internationally and selling and shipping our products and purchasing our products and components internationally;

●

Fluctuations in foreign currency exchange rates and interest rates;

●

Failure to develop new products and technologies, delays in new product introduction and lack of market acceptance of new products;

●

Exposure to assertions of intellectual property claims and failure to protect our intellectual property;

●

Disruption in our ability to manufacture our products or the ability of our key suppliers to provide us products or components or raw materials for products resulting in our inability to supply market demand for our products;

●

Reliance on independent sales distributors and sales associates to market and sell our products;

●

Highly competitive nature of the markets in which we sell our products and the introduction of competing products;

●

Loss of customers;

●

Failure to retain senior management or replace lost senior management;

●

Reliance on our management information systems for inventory management, distribution, accounting and other functions;

●

Effects of any potential litigation;

●

Failure to comply with applicable laws and regulations and adverse changes in applicable laws or regulations; or

●

Changes in generally accepted accounting principles

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

  

Foreign Currency Risk

 

Historically, in excess of 60% of our consolidated sales have been to international destinations. In our U.S. operations, we invoice most of these customers in U.S, dollars, so we do not have significant exposure to foreign currency transaction risk. In our European based operations, we have some exposure to foreign currency fluctuations as we invoice our customers primarily in euros, Danish krone and U.S. dollars. From time to time we use foreign exchange hedging contracts to reduce our exposure in these transactions. We also pay a small number of our international suppliers in their local currency which exposes us to transaction gain or loss. However, these have not resulted in material amounts in the past.

 

 

Our foreign operations expose us to foreign currency exchange risk when the Danish krone, euro and yuan currency results of operations are translated to U.S. dollars. We historically have not experienced any material foreign currency translation gains or losses, however, we are exposed to foreign currency transaction gains or losses related to the valuation of our seller loan obligation dominated in Danish krone. To mitigate the effect of any further currency fluctuations in our loan obligations for Dansensor, we purchased a foreign currency contract which acted as an economic hedge against any additional gains or losses.

 

Our investments in foreign subsidiaries translated into U.S. dollars are not hedged. Any changes in foreign currency exchange rates would be reflected as a foreign currency translation adjustment, a component of accumulated other comprehensive income in stockholders’ equity, and would not impact our net income.

 

 

 

Item 4.         Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) that are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934 (Exchange Act), as amended, is recorded, processed, summarized, and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we necessarily are required to apply our judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this Quarterly Report on Form 10-Q. Based on the evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that the material weaknesses identified in connection with our consolidated financial statements for the year ended December 31, 2013 were not effectively remediated as of June 30, 2014, due to the fact that an insufficient period of time has passed for management to thoroughly test and document the effectiveness of our disclosure controls and procedures and, accordingly, the disclosure controls and procedures were not effective as of June 30, 2014.

 

Changes in Internal Control Over Financial Reporting

 

There was no change in our internal control over financial reporting that occurred during our quarter ended June 30, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, except for the on-going remediation efforts to address the material weakness in internal controls.

 

 

PART II.     OTHER INFORMATION

 

Item 1.

Legal Proceedings

 

None.

 

Item 1A.

Risk Factors

 

We are affected by risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results or could cause our actual results to differ materially from our expectations are described in our annual report on Form 10-K for the fiscal year ended December 31, 2013 under the heading “Part I – Item 1A. Risk Factors.” There has been no material change in those risk factors.

 

 

 

Item 2.

Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities

 

Unregistered Sales of Equity Securities

 

We did not sell any equity securities of MOCON, Inc. during the three and six-month period ended June 30, 2014 that were not registered under the Securities Act of 1933.

 

 

Issuer Repurchases of Equity Securities

 

Other than the withholding of 1,671 shares of our common stock in connection with the cashless net exercise of stock options to pay the exercise price of such options, we did not repurchase any equity securities of MOCON, Inc. during the three months ended June 30, 2014.

 

Item 3.

Defaults Upon Senior Securities

 

None.

 

Items 4.

Mine Safety Disclosures

 

None.

 

Item 5.

Other Information

 

None.

 

Item 6.

Exhibits

 

The following exhibits are being filed or furnished with this quarterly report on Form 10-Q:

 

Exhibit No.		Description
31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.1		Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
32.2		Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
101		The following materials from MOCON, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, formatted in XBRL (Extensible Business Reporting Language): (i) the unaudited Condensed Consolidated Balance Sheets, (ii) the unaudited Condensed Consolidated Statements of Income, (iii) the unaudited Condensed Consolidated Statements of Comprehensive Income, (iv) the unaudited Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	MOCON, INC.
Date: August 8, 2014	/s/ Robert L. Demorest
	Robert L. Demorest
	Chairman, President and Chief
	Executive Officer
	(Principal Executive Officer)
Date:  August 8, 2014	/s/ Darrell B. Lee
	Darrell B. Lee
	Vice President, Treasurer and Chief
	Financial Officer
	(Principal Financial and Accounting Officer)

  

 

MOCON, INC.

QUARTERLY REPORT ON FORM 10-Q

QUARTER ENDED JUNE 30, 2013

 

EXHIBIT INDEX

 

Exhibit No.		Description
31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.1		Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
32.2		Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
101		The following materials from MOCON, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, formatted in XBRL (Extensible Business Reporting Language): (i) the unaudited Condensed Consolidated Balance Sheets, (ii) the unaudited Condensed Consolidated Statements of Income, (iii) the unaudited Condensed Consolidated Statements of Comprehensive Income, (iv) the unaudited Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.

 

 

 

-28-